NasdaqCM - Nasdaq Real Time Price USD

IceCure Medical Ltd (ICCM)

1.0300

0.0000

(0.00%)

At close: May 9 at 4:00:00 PM EDT

1.0400

+0.01

+(0.97%)

After hours: May 9 at 7:48:38 PM EDT

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates

Natera (NTRA) delivered earnings and revenue surprises of 15.25% and 13.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 days ago

ICCM
0.00%
IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it participated in the American Society of Breast Surgeons (ASBrS) 2025 Annual Meeting on April 30 – May 4, 2025 in Las Vegas.

PR Newswire 4 days ago

ICCM
0.00%
IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it concluded a productive meeting with the leadership of the U.S. Food and Drug Administration's ("FDA") Center for Devices and Radiological Health ("CDRH") regarding the Company's De Novo marketing authorization request for ProSense® in the treatment of early-stag

PR Newswire 10 days ago

ICCM
0.00%
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation at the Society of Breast Imaging (SBI) 2025 Breast Imaging Symposium which took place April 24-27, 2025 in Colorado Springs, Colorado.

PR Newswire 12 days ago

ICCM
0.00%
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation in the European Conference on Interventional Oncology 2025 (ECIO), which took place on April 13 – 16, 2025 in Rotterdam, the Netherlands. One of the major areas of focus at ECIO 2025 was breast cancer cryoablation, with ProSense® featuring in seve

PR Newswire 18 days ago

ICCM
0.00%
IceCure Medical Stock Dips Despite Positive ICESECRET Study Results

ICCM reports strong kidney cancer cryoablation study results, showcasing 88.7% recurrence-free rates and reinforcing its position in cryoablation technology.

Zacks last month

ICCM
0.00%

MASI

BSX
IceCure Medical Full Year 2024 Earnings: Misses Expectations

IceCure Medical ( NASDAQ:ICCM ) Full Year 2024 Results Key Financial Results Revenue: US$3.29m (up 1.9% from FY 2023...

Simply Wall St. last month

ICCM
0.00%
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the twelve months ended December 31, 2024.

PR Newswire last month

ICCM
0.00%
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that interim results from the Company's ICESECRET study of cryoablation for patients with small renal masses ("SRM") who cannot be offered kidney preserving surgery were presented at the European Association of Urology Conference in Madrid, Spain which took place M

PR Newswire last month

ICCM
0.00%
IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2024 before the Nasdaq Stock Market opens on Thursday, March 27, 2025. The Company will also discuss such results and other corporate de

PR Newswire last month

ICCM
0.00%
IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it is in continued discussions with the U.S. Food and Drug Administration ("FDA") regarding its De Novo marketing authorization request for ProSense® in early-stage low risk breast cancer with endocrine therapy. The Company now expects the FDA's marketing authoriza

PR Newswire last month

ICCM
0.00%
IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it exhibited at the 19th Annual St. Gallen Breast Cancer Conference in Vienna, Austria from March 12 – 15, 2025. Six studies of ProSense® in breast cancer were accepted as peer-reviewed abstracts, presented as e-posters during the conference, and are being pub

PR Newswire last month

ICCM
0.00%
IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a Notice of Allowance for its invention titled "Cryogenic System Connector" from the China National Intellectual Property Administration.

PR Newswire last month

ICCM
0.00%
Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an independent study titled 'Post-treatment patient satisfaction in early-stage breast cancer: Comparison of cryoablation versus breast conservation therapy using BREAST-Q' in the peer reviewed journal Gland Surgery. The study was conducted at th

PR Newswire last month

ICCM
0.00%
IceCure seeks Israeli regulatory approval for XSense cryoablation system

The company's submission includes a request to approve the system for all indications currently authorised for its ProSense system.

Medical Device Network 2 months ago

ICCM
0.00%
IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has filed for regulatory approval with the Medical Device Division ("AMAR") of Israel's Ministry of Health for its next-generation single cryoprobe cryoablation system, the XSense™ System and CryoProbes.

PR Newswire 2 months ago

ICCM
0.00%
IceCure Medical Ltd's (NASDAQ:ICCM) Profit Outlook

With the business potentially at an important milestone, we thought we'd take a closer look at IceCure Medical Ltd's...

Simply Wall St. 2 months ago

ICCM
0.00%
IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation as one of the sponsors of the Breast Cryoablation Mini Masterclass held during the 2025 Society of Interventional Oncology (SIO) Annual Meeting in Las Vegas, which took place January 29 to February 3, 2025.

PR Newswire 3 months ago

ICCM
0.00%
IceCure submits application to China’s NMPA for cryoablation system approval

ProSense uses liquid nitrogen, which creates extensive lethal zones to destroy benign and malignant lesions.

Medical Device Network 3 months ago

ICCM
0.00%
IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has submitted a regulatory filing with China's National Medical Products Administration ("NMPA") for the approval of its ProSense® Cryoablation System. IceCure's IceSense3, its predecessor cryoablation system, already has regulatory approval in China.

PR Newswire 3 months ago

ICCM
0.00%

Performance Overview

Return	ICCM	S&P 500 (^GSPC)
YTD	-6.36%	-3.77%
1-Year	-11.97%	+8.55%
3-Year	-44.62%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

IceCure Medical Ltd (ICCM)

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

IceCure Medical Stock Dips Despite Positive ICESECRET Study Results

IceCure Medical Full Year 2024 Earnings: Misses Expectations

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

IceCure seeks Israeli regulatory approval for XSense cryoablation system

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

IceCure Medical Ltd's (NASDAQ:ICCM) Profit Outlook

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

IceCure submits application to China’s NMPA for cryoablation system approval

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

Performance Overview